Genmab Announces European Conditional Marketing Authorization for DARZALEX(r) (daratumumab) for Multiple Myeloma
Company Announcement DARZALEX (daratumumab) receives European conditional marketing authorization for heavily pre-treated or double refractory multiple myeloma First CD38 monoclonal antibody approved in Europe COPENHAGEN, Denmark, May 23, 2016 (GLOBE …